Clinical Guides
Barrett's Oesophagus
A clinically focused guide to diagnosing and managing Barrett's oesophagus in Indian practice, with disciplined endoscopy and pathology, risk-stratified surveillance, dysplasia confirmation, ablation pathways and explicit evidence limits.
MedNext Academy | 12 min read
Barrett's Oesophagus
A clinically focused guide to diagnosing and managing Barrett's oesophagus in Indian practice, with disciplined endoscopy and pathology, risk-stratified surveillance, dysplasia confirmation, ablation pathways and explicit evidence limits.
Summary
Barrett's oesophagus is a metaplastic change in the distal tubular oesophagus associated with gastro-oesophageal reflux and an increased risk of oesophageal adenocarcinoma. It has no distinctive symptom: patients are usually investigated because of reflux, risk factors or an unrelated indication. Diagnosis requires high-quality endoscopic identification of a sufficiently long columnar-lined segment above the gastric folds and, under the American College of Gastroenterology definition used here, biopsy confirmation of intestinal metaplasia. An irregular Z-line less than one centimetre should not be casually labelled Barrett's or enrolled in surveillance. Endoscopy must document landmarks and segment extent using the Prague classification, inspect carefully for visible lesions, and sample according to a structured protocol. Any dysplasia diagnosis should be confirmed by an expert gastrointestinal pathologist because inflammation and interobserver variation can change management. Non-dysplastic disease is managed with reflux control and length-stratified surveillance, not routine ablation. Confirmed low-grade dysplasia warrants discussion of endoscopic eradication therapy versus surveillance; high-grade dysplasia or appropriate intramucosal neoplasia generally requires endoscopic therapy in an expert centre. Visible lesions are resected for staging before the remaining Barrett's field is ablated. Surgery is not routine cancer prevention and is reserved for usual antireflux or oncological indications. Indian application must acknowledge variable endoscopy quality, pathology access, affordability and follow-up reliability. Surveillance reduces risk only when the baseline diagnosis, sampling, histology and recall system are dependable.
How Common Is It?
Prevalence depends strongly on who undergoes endoscopy, how Barrett's is defined, whether intestinal metaplasia is required and the population's reflux, obesity, smoking and demographic profile. It is more frequent among people with chronic reflux and multiple risk factors than in unselected adults, yet most people with reflux do not have Barrett's and most with non-dysplastic Barrett's never develop cancer. Published Western estimates cannot be transferred directly to India because background risk, referral thresholds and diagnostic practice differ. Indian endoscopy series are often hospital-based and may overrepresent symptomatic or affluent patients; they do not establish a national prevalence. The absolute annual progression risk from non-dysplastic Barrett's to adenocarcinoma is low, which is why indiscriminate screening and ablation can cause more burden than benefit. Risk rises with confirmed dysplasia, longer segments and certain clinical factors, but no routine biomarker panel currently replaces careful histology and endoscopy. Apparent increases over time may reflect greater endoscopy access, altered definitions and better recognition as well as true epidemiological change. For practice, prevalence figures are less useful than disciplined selection: screen only patients whose combined risk profile makes a one-time examination reasonable, and avoid repeating a negative high-quality screening endoscopy without another indication. Local services should audit the proportion of suspected cases with correct landmarks, Prague measurements, adequate biopsies and specialist pathology confirmation rather than claiming population coverage from procedure counts.
Risk Factors
Chronic gastro-oesophageal reflux is the principal clinical association, but symptom severity does not measure metaplasia or cancer risk. Guideline screening strategies combine prolonged reflux with several additional factors such as age over 50 years, male sex, central obesity, tobacco exposure, family history of Barrett's or oesophageal adenocarcinoma, and population background. Race-based variables in North American guidance should not be applied mechanically to India's diverse populations or used as biological absolutes. A first-degree family history can materially alter the discussion. Once Barrett's is established, longer segment length, confirmed dysplasia, smoking and obesity are associated with higher progression risk. Absence of heartburn is not protective, and women can develop Barrett's; screening thresholds simply reflect differing average yields and harms. Alcohol is not a reliable standalone screening criterion. The clinical assessment should record reflux duration and control, dysphagia, bleeding, weight loss, tobacco use, waist or body mass index, family cancer history, prior endoscopy, medicines, comorbidity and fitness for possible therapy. Screening has little value if the patient would not accept or safely undergo surveillance and treatment. Risk calculators and biomarkers remain adjunctive research tools rather than substitutes for the guideline pathway. A risk factor is not a diagnosis: endoscopic suspicion without appropriate location, length and histology should not trigger lifelong surveillance, and normal reflux symptoms should not reassure against an alarm presentation.
Diagnosis
History
Elicit reflux duration, regurgitation, nocturnal symptoms and response to therapy, but explain that Barrett's itself is usually silent. Ask about dysphagia, odynophagia, gastrointestinal bleeding, anaemia symptoms, early satiety and weight loss because these require diagnostic rather than screening endoscopy. Record smoking, central obesity, family history, previous reports and whether the person could complete follow-up. Confirm what prior pathology actually showed rather than accepting a problem-list label.
Examination
There is no diagnostic physical sign. Assess weight, central adiposity, anaemia, nutrition, lymphadenopathy and abdominal or hepatic abnormalities when cancer is a concern. Examination guides urgency and fitness; it neither confirms nor excludes metaplasia.
Investigations
Use high-definition white-light endoscopy with careful cleaning, insufflation and inspection. Identify the diaphragmatic pinch, top of gastric folds and squamocolumnar junction; report circumferential and maximal extent with Prague C and M values. Do not routinely biopsy a normal Z-line or less-than-one-centimetre irregularity without a visible abnormality. Sample every visible lesion separately, then use a structured four-quadrant protocol through the remaining segment. Pathology should state intestinal metaplasia and grade any dysplasia. Indefinite or dysplastic diagnoses require review by an experienced gastrointestinal pathologist, ideally blinded to the first opinion. Active oesophagitis can obscure or mimic change, so optimise acid control and repeat assessment when indicated. For visible neoplasia, endoscopic resection provides histological staging. Cross-sectional imaging and multidisciplinary staging are used when invasion or cancer extent is suspected, not for routine non-dysplastic disease.
Differential Diagnosis
The first distinction is anatomical. Gastric cardia intestinal metaplasia sampled below the top of gastric folds is not Barrett's oesophagus, and a less-than-one-centimetre irregular Z-line has extremely low progression risk and should not be converted into a surveillance diagnosis without a visible lesion. Reflux oesophagitis can create tongues, islands, ulceration and reactive atypia; healing before final grading may prevent overdiagnosis. A hiatal hernia can distort landmarks, especially with over-insufflation. Inlet patches are proximal gastric-type mucosa and should not be confused with distal Barrett's. Eosinophilic oesophagitis, infectious oesophagitis, pill injury and caustic damage have different clinical and histological patterns. Reactive or regenerative atypia may be reported as indefinite for dysplasia rather than true low-grade disease. Expert pathology review is critical because community and specialist interpretations often disagree, particularly at the low-grade threshold. Squamous dysplasia and squamous carcinoma follow a separate pathway from Barrett-associated adenocarcinoma. A visible nodule, ulcer, depression or irregularity may contain early cancer even when surrounding random biopsies show a lower grade; targeted endoscopic resection is therefore diagnostic and therapeutic. Invasive adenocarcinoma must be staged rather than treated as uncomplicated dysplasia. Finally, functional heartburn and reflux hypersensitivity may explain symptoms but do not cause or exclude Barrett's. Management should follow the highest-quality confirmed anatomical and histological finding, not the most alarming unverified label in a referral letter.
Management
For non-dysplastic Barrett's, treat reflux, address tobacco and weight where relevant, and enrol suitable patients in quality-assured surveillance at an interval based chiefly on segment length and the governing guideline. Routine endoscopic eradication therapy is not recommended because absolute cancer progression risk is low and procedures can cause pain, bleeding and stricture. ACG guidance uses five-year surveillance for segments under three centimetres and three-year surveillance for segments at least three centimetres after a high-quality baseline examination; local programmes must choose and document one current standard rather than mix intervals. Confirmed low-grade dysplasia should be reviewed by expert pathology and discussed in a specialist multidisciplinary setting. Endoscopic eradication therapy reduces progression, but surveillance is a reasonable alternative for some patients after transparent discussion of benefit uncertainty, procedure burden and follow-up. High-grade dysplasia generally warrants eradication therapy rather than observation. Resect visible lesions first with endoscopic mucosal resection or selected endoscopic submucosal dissection to establish depth, differentiation, margins and lymphovascular invasion; then ablate residual flat Barrett's, commonly using radiofrequency or an appropriate alternative. Continue structured surveillance after complete eradication because recurrence occurs. Antireflux surgery can be considered for refractory reflux according to ordinary surgical indications, but it should not be offered solely as an antineoplastic measure. Invasive or high-risk cancer requires oesophagogastric multidisciplinary staging and may need surgery or oncological therapy rather than an ablation-only pathway.
Prescribing Information
The ACG guideline suggests at least once-daily proton-pump inhibitor therapy for patients with Barrett's who have no allergy or contraindication. Dose should be increased only for an appropriate clinical reason, such as inadequate symptom control, erosive oesophagitis or preparation for reassessment of inflammation, rather than assumed chemoprevention benefit. Review adherence, timing before food, interactions and the ongoing indication. Discuss recognised PPI adverse effects proportionately; observational associations do not prove causation, and abrupt discontinuation may allow reflux injury to recur. H2-receptor antagonists can help selected symptoms but are not an evidence-equivalent substitute for the Barrett pathway. Aspirin, non-steroidal anti-inflammatory medicines and statins should not be initiated solely as Barrett chemoprevention on the basis of this guide; use their cardiovascular or other standard indications while considering bleeding, renal and interaction risks. Endoscopic eradication is a procedure, not a prescription: analgesia, acid suppression and post-procedure diet vary by technique and centre. After resection or ablation, new severe chest pain, fever, haematemesis, dyspnoea or inability to swallow requires urgent evaluation. Dysphagia developing during a treatment course may reflect a stricture requiring endoscopic assessment. Antithrombotic management must be individualised to procedural bleeding risk and thrombotic indication. A medication list cannot replace surveillance, and good symptom control does not prove histological regression or eliminate adenocarcinoma risk.
When to Refer
Refer for diagnostic endoscopy when alarm symptoms such as progressive dysphagia, bleeding, iron-deficiency anaemia, persistent vomiting or unexplained weight loss accompany reflux; this is not elective Barrett screening. Consider routine screening referral only when chronic reflux coexists with enough additional risk factors and when the patient could benefit from subsequent surveillance or treatment. Any suspected Barrett segment should be evaluated by an endoscopist able to document landmarks, Prague extent, visible lesions and a structured biopsy plan. Refer indefinite, low-grade or high-grade dysplasia for expert gastrointestinal pathology review before changing management. Confirmed dysplasia, a visible lesion or early neoplasia belongs in a specialist centre with advanced imaging, resection, ablation, surgical backup, audited outcomes and a multidisciplinary team. Complex strictures, nodularity, suspected submucosal invasion, lymphovascular invasion, poor differentiation or deeper cancer require oesophagogastric cancer assessment rather than routine ablation. Referral is also appropriate when surveillance quality was poor, biopsy numbers were inadequate, the segment length is uncertain or the original slides cannot be reviewed. In India, explicitly match the referral to the missing capability: high-quality diagnostic endoscopy, specialist pathology, therapeutic endoscopy, surgery or oncology. Give the receiving centre prior reports, images, histology blocks or slides and procedure details. A patient should not be lost between pathology confirmation and therapy; closed-loop recall and named responsibility are part of safe referral.
Red Flags
Progressive or new dysphagia, odynophagia, gastrointestinal bleeding, iron-deficiency anaemia, persistent vomiting, unexplained weight loss, early satiety, palpable nodes or constitutional decline require urgent diagnostic evaluation for cancer or another complication. Acute haematemesis, melaena with instability, severe chest pain or inability to swallow demands emergency assessment rather than a surveillance appointment. At endoscopy, nodularity, ulceration, depression, spontaneous bleeding, focal mucosal irregularity or a stricture within Barrett's may harbour neoplasia and should be characterised and sampled or resected by an appropriately skilled endoscopist. High-grade dysplasia should not remain on an ordinary surveillance waiting list. A pathology report of dysplasia without expert confirmation is a decision warning: acting on an overcall can expose a patient to unnecessary eradication, while dismissing a true finding delays cancer prevention. After endoscopic resection or ablation, severe pain, fever, tachycardia, dyspnoea, haematemesis, melaena or inability to tolerate liquids may signal perforation, bleeding or significant stricture. Persistent reflux after therapy needs review, but symptoms alone do not define recurrence. A missed recall is a system red flag; surveillance programmes should actively trace patients rather than assume non-attendance is informed refusal. Finally, invasive features on resection pathology, including submucosal invasion, poor differentiation or lymphovascular invasion, mandate multidisciplinary staging because endoscopic eradication of the remaining mucosa is not sufficient cancer treatment.
Indian Clinical Context
The evidence base and major surveillance algorithms arise largely from Western populations and specialist systems. India has heterogeneous reflux patterns, cancer epidemiology, endoscopy quality, pathology access and capacity to fund repeated procedures; locally quoted prevalence figures are often referral-centre estimates rather than national data. Applying the pathway safely therefore depends on quality before volume. Endoscopy reports should include photographs of landmarks, Prague C and M measurements, lesion mapping and biopsy sites. Pathology services need access to gastrointestinal expertise for dysplasia review; when local review is unavailable, slides or digital images should be referred before ablation. Radiofrequency ablation, endoscopic mucosal resection, endoscopic submucosal dissection and oesophageal surgery are not interchangeable simply because a hospital offers one of them. Patients may travel long distances and pay out of pocket, so counselling should include the number of expected treatment sessions, stricture risk, post-eradication surveillance and the consequences of interrupted follow-up. A lower-cost but incomplete procedure is not necessarily economical. Recall systems should use consented phone or digital contact while protecting privacy and documenting responsibility. Lifestyle counselling should be culturally and economically practical, focusing on weight, tobacco and symptom triggers without claiming that a particular Indian food reverses metaplasia. Where follow-up cannot be assured, this limitation belongs in shared decision-making and service design, not in a false promise that one ablation session eliminates future cancer risk.
NMC Competency Mapping
Barrett's oesophagus supports integrated undergraduate learning in gastrointestinal history, reflux assessment, dysphagia triage, cancer warning signs and rational investigation. SU28.5 covers applied oesophageal anatomy and physiology, and SU28.6 covers clinical features, investigations and management principles for benign and malignant oesophageal disorders. PA23.2 addresses the aetiology, pathogenesis, pathology and clinical and microscopic features of carcinoma oesophagus, providing the neoplasia link without implying that every Barrett segment becomes malignant. Learners should distinguish screening from diagnosis: a stable high-risk reflux patient may be considered for screening, whereas dysphagia or weight loss demands prompt diagnostic endoscopy. They should understand junctional landmarks, intestinal metaplasia, why a tiny irregular Z-line is not equivalent to Barrett's, and why visible lesions take priority over random biopsies. Pathology integration includes reactive atypia, low-grade dysplasia, high-grade dysplasia and invasive adenocarcinoma, with specialist confirmation changing treatment. Pharmacology outcomes include appropriate PPI use and avoidance of unsupported chemoprevention claims. Communication includes explaining low absolute progression risk, obtaining consent for surveillance, and discussing uncertainty and affordability. Patient-safety assessment should test alarm features, procedure complications and acting on unconfirmed dysplasia. Surveillance intervals are meaningful only after a high-quality baseline examination, verified segment length, adequate biopsies and trustworthy histology.
Key Exam Pearls for NEET PG
Barrett's oesophagus is intestinal-type columnar metaplasia in the tubular oesophagus in the ACG definition; it is associated with reflux and is the recognised precursor of oesophageal adenocarcinoma. It causes no specific symptom, so new dysphagia or weight loss must be treated as an alarm presentation rather than blamed on Barrett's. Identify the top of gastric folds before calling a distal biopsy oesophageal. A normal Z-line or less-than-one-centimetre irregular Z-line without a lesion should not receive routine biopsies or surveillance. Report extent with Prague C and M values. Inspect and biopsy visible abnormalities first, then apply a systematic four-quadrant protocol to the remaining segment. Dysplasia requires confirmation by an expert gastrointestinal pathologist. Non-dysplastic Barrett's receives acid suppression and surveillance; routine ablation is inappropriate. Longer segments receive shorter surveillance intervals under current ACG guidance. Confirmed low-grade dysplasia can be managed with endoscopic eradication therapy or structured surveillance after shared decision-making, whereas high-grade dysplasia usually requires eradication therapy. Resect a visible lesion before ablating flat residual Barrett's because histology determines depth and curability. Endoscopic therapy is preferred for suitable mucosal neoplasia, but invasive or high-risk pathology requires cancer-team staging and possible surgery. Antireflux surgery is not recommended solely to prevent cancer. After successful eradication, surveillance continues because intestinal metaplasia or neoplasia can recur. Biomarkers and aspirin chemoprevention have not replaced standard endoscopy, pathology and reflux care.
Frequently Asked Questions
Does every person with long-term acid reflux need screening for Barrett's oesophagus?
No. Guidelines favour a one-time screening discussion for selected people with chronic reflux plus multiple additional risk factors, not universal endoscopy. Age, sex, central obesity, smoking and family history contribute, while local disease patterns and fitness for follow-up matter. Alarm symptoms such as dysphagia, bleeding or weight loss are different: they require diagnostic endoscopy regardless of whether a screening threshold is met.
Should non-dysplastic Barrett's oesophagus be ablated to prevent cancer?
Routine ablation is not recommended. Most people with non-dysplastic disease have a low absolute progression risk, while eradication therapy creates procedure burden and risks such as pain, bleeding and stricture. Management generally combines reflux treatment and length-based surveillance. Ablation becomes appropriate mainly for confirmed dysplasia or selected early neoplasia after specialist pathology review and informed discussion.
Why is a second pathology review needed before treating dysplasia?
Reactive inflammation and genuine dysplasia can be difficult to distinguish, and agreement is imperfect, especially for low-grade change. An expert gastrointestinal pathologist may downgrade or confirm the diagnosis, which directly changes whether the patient receives surveillance or eradication therapy. Review should use the original slides or high-quality digital material and should occur before an irreversible treatment decision whenever clinically possible.
Is surveillance finished after successful Barrett's ablation?
No. Even after complete eradication of visible intestinal metaplasia, recurrence and metachronous neoplasia can occur. Follow-up endoscopy uses intervals based on the pretreatment grade, careful inspection and targeted sampling under the chosen guideline. Reflux control and symptom review continue, but symptoms cannot replace endoscopic assessment. A written recall plan and responsibility for arranging it are essential.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic